FASN and neoplasm: Early studies using broader spectrum inhibitors targeting specific domains of FASN demonstrated decreased viability of cancer cells and restrained tumor growth in xenograft models as a consequence of FASN inhibition [19,20,21,22,23,24,25,26] but these compounds were limited by poor solubility, poor bioavailability, and off-target toxicity [2,18,27].